Brief: Nicox Announces Plans For NCX 4251 Phase 2 Trial In Blepharitis

Nicox SA

13/10/2020 07:03

Oct 13 (Reuters) - Nicox SA  NCOX.PA :
    * ANNOUNCES PLANS FOR NCX 4251 PHASE 2 TRIAL IN BLEPHARITIS
    * MISSISSIPPI PHASE 2 TRIAL WILL EVALUATE ONCE-DAILY DOSED
NCX
4251 0.1% AGAINST PLACEBO IN BLEPHARITIS PATIENTS

Source text for Eikon:  ID:nGNE7XKjnc 
Further company coverage:  NCOX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))